Sarcomatoid mesothelioma (SM) is an exceptional and fierce subtype of mesothelioma, a cancer arising from the mesothelial cells covering the pleura, peritoneum, pericardium, or tunica vaginalis. Protheragen provides an SM-focused comprehensive suite of services for developing diagnostics and therapeutics.
Overview of Sarcomatoid Mesothelioma (SM)
Sarcomatoid mesothelioma (SM) is one of the uncommon and extremely aggressive forms of mesothelioma. It is characterized by its spindle-shaped cells and has the ability to grow and invade tissues rapidly. This variant of mesothelioma has one of the worst prognoses with an average survival of less than one-year post-diagnosis. SM is most commonly associated with the long-term use of asbestos fibers that cause long-term inflammation and genetic changes in mesothelial cells. Due to the non-specific clinical cough, chest pain, and dyspnea that resemble benign pneumonia, the diagnosis of SM is often late.
Fig.1 A case study of histopathological analysis of sarcomatoid mesothelioma (SM). (Zuccatosta L.,
et al., 2023)
Pathogenesis of Sarcomatoid Mesothelioma (SM)
The main cause of sarcomatoid mesothelioma is due to asbestos exposure, a naturally occurring fibrous mineral, resulting from prolonged exposure. Inhaled asbestos fibers can become lodged in the pleura, which can lead to chronic inflammation and oxidative stress. These processes can cause genetic mutations and epigenetic changes in mesothelial cells that malignant transform. In SM, some critical genetic changes are the loss of methylthioadenosine phosphorylase, as well as a homozygous deletion of cyclin-dependent kinase inhibitor 2A (CDKN2A), which is known to lead to aggressive disease progression and a poor prognosis. Tumor growth can also be caused by the changes in the expression of some genes due to modifications in DNA methylation and the modification of histones, which greatly alter the expression of genes.
Diagnostics Development for Sarcomatoid Mesothelioma (SM)
- Immunohistochemical Markers
BAP1 and Claudin-4 are among the most widely researched biomarkers for SM diagnosis. BAP1 loss is particularly significant, as it occurs in nearly 56% of SM cases, distinguishing it from other sarcomatoid tumors. Meanwhile, Claudin-4 is typically absent in SM, serving as a useful negative marker when differentiating mesothelioma from sarcomatoid carcinoma. Other markers like WT1, D2-40, and calretinin also show varying degrees of sensitivity and specificity.
- Diagnostic Imaging Modalities
Preclinical diagnostic development for sarcomatoid mesothelioma involves the use of various imaging techniques to detect and monitor tumor progression. Techniques such as CT (computed tomography) and PET (positron emission tomography) scans are commonly used to visualize tumor burden, pleural thickening, and metastasis. However, these methods lack specificity for differentiating SM from other sarcomatoid malignancies, such as sarcomatoid carcinoma.
- Molecular Diagnostics
Emerging molecular diagnostic methods, such as NGS and fluorescence in situ hybridization (FISH), are being integrated into preclinical diagnostics for SM. These techniques help identify specific mutations, such as CDKN2A homozygous deletions and MTAP loss, that are characteristic of SM. These molecular markers allow for a more precise diagnosis and have the potential to guide therapeutic decisions, including personalized therapies targeting the genetic abnormalities.
Therapeutics of Sarcomatoid Mesothelioma (SM)
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Chemotherapy |
Pemetrexed |
Inhibits folate-dependent enzymes |
Pemetrexed is a multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to reduced DNA synthesis and repair. |
Approved |
| Chemotherapy |
Cisplatin |
DNA cross-linking |
Cisplatin forms covalent bonds with DNA, leading to DNA damage and apoptosis. |
Approved |
| Trimodality Therapy (TMT) |
Pemetrexed + Cisplatin + Radiotherapy |
A combination of chemotherapy and radiotherapy |
TMT involves extrapleural pneumonectomy (EPP) with neoadjuvant or adjuvant chemotherapy and adjuvant radiotherapy. |
Approved |
| Molecular Targeted Therapy |
Not specified |
Targeting specific genetic mutations |
Targeted therapies focus on specific genetic mutations and pathways involved in SM, such as MTAP and CDKN2A. |
Early studies |
| CTLA-4/CD152 Inhibitors |
Not specified |
Modulate immune response |
CTLA-4 inhibitors enhance the immune response by blocking inhibitory signals on T cells. |
Early studies |
| Regulatory T-cell Depletion |
Not specified |
Enhance immune response |
Depletion of regulatory T cells to inhibit tumor repopulation between chemotherapy cycles. |
Early studies |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen provides comprehensive diagnostics and therapeutics development services for sarcomatoid mesothelioma. Our diagnostic offerings include advanced techniques such as immunohistochemistry, electron microscopy, and fluorescence in situ hybridization. We also focus on developing targeted therapies and immunotherapies, utilizing our expertise in molecular biology and preclinical research to drive innovative solutions.
Disease Models
- Organoid Models of Sarcomatoid Mesothelioma
- Asbestos Exposure Models
- Genetically Engineered Mice
- Syngeneic Subcutaneous Models
- Orthotopic Models
At Protheragen, we understand that each client's needs are unique. Therefore, we offer customized services tailored to meet the specific requirements of our clients. Whether it's designing a bespoke preclinical study or developing a diagnostic assay, our team works closely with our clients to ensure that their objectives are met efficiently and effectively. If you are interested in our services, please feel free to contact us.
References
- Zuccatosta, Lina, et al. "Immunohistochemistry for Claudin-4 and BAP1 in the differential diagnosis between sarcomatoid carcinoma and sarcomatoid mesothelioma." Diagnostics 13.2 (2023): 249.
- Clopton, Brittni, et al. "Sarcomatoid mesothelioma: unusual findings and literature review." Journal of Surgical Case Reports 2022.11 (2022): rjac512.
- Yoshida, Miho, et al. "Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma." Diagnostic Pathology 18.1 (2023): 126.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
